Supreme Court Requires More Oversight Over PTAB In Arthrex Decision, a Cantor Colburn Client Alert written by Post-Grant Practice Chair Andrew Ryan."The Supreme Court finds that the USPTO Director has ultimate oversight over PTAB decisions .... IPR procedures are expected to remain intact largely as is." 

Cantor Colburn's Client Alert addresses the Federal Circuit's decision on establishing venue in Hatch-Waxman suits.

The U.S. Court of Appeals for the Federal Circuit rejected drug maker Allergan PLC’s attempt to shield its highly profitable Restasis patents from inter partes review (IPR) challenges by transferring them to a Native American tribe, as discussed in Cantor Colburn's Client Alert.

Cantor Colburn LLP has been recommended as a Leading Firm by the Legal 500 United States 2018 in Intellectual Property for Patents: prosecution (including re-examination and post-grant proceedings). This is the ninth consecutive year that Cantor Colburn has been recognized for this highly selective honor.

On April 24, 2018, the Supreme Court issued two important decisions in the cases of Oil States Energy Services, LLC v. Greene’s Energy Group, LLC, et al., and SAS Institute Inc. v. Iancu, addressing inter partes review (IPR). Both cases will have a significant impact on IPR proceedings. In sum and as discussed in greater detail in Cantor Colburn's Client Alert, the Court determined that (1) IPR proceedings are indeed constitutional, and (2) the Patent Trial and Appeal Board (PTAB) must address all challenged claims in the final written decision.  

Anne Maxwell, Andrew Ryan, Steve Coyle, Christopher Potts, and Derek Denhart co-wrote the article "Will Biosimilar Applicants Opt Out of Patent Dance? Federal Court Ruling to Have Impact on Future Litigation Strategies," published by the Connecticut Law Tribune on April 20, 2015.

Members of Cantor Colburn's Pharmaceutical IP Services Practice Group co-authored an article on biosimilars entitled "BPCIA: How Long Does The Party Last And Do I Have To Dance?" that appeared in Law360 on March 24, 2015.  Leslie-Anne Maxwell, Andrew Ryan, Christopher Potts and Derek Denhart wrote the article which discusses Amgen Inc. v. Sandoz Inc.

Partner Andrew Ryan comments in Law360's March 20, 2015 article on Amgen Inc. v Sandoz Inc., "3 Things To Watch After Sandoz's Biosimilars Win."

Cantor Colburn litigator Andrew Ryan wrote an analysis of the U.S. Court of Appeals for the Federal Circuit first-ever ruling in an appeal from an inter partes review in In re Cuozzo Speed Technologies LLC, published in Law360 on February 4, 2015.

The U.S. Supreme Court on January 20, 2015 cast aside the Federal Circuit's long-standing rule that all district court claim construction rulings must be reviewed anew on appeal.  Cantor Colburn litigation partner Andrew Ryan and other litigators tell Law360 why the decision in Teva Pharmaceuticals v. Sandoz is significant.

Cantor Colburn Litigation Partner Andrew C. Ryan and Associate Chad A. Dever wrote the article, "A New Era in Intellectual Property Law," published by The Connecticut Law Tribune on December 29, 2014.  

The 2012 America Invents Act ushered in three new procedures that allow a petitioner to challenge the validity of one or more patent claims after they have been granted by the PTO:  inter partes review, post grant review, and covered business method. This article by Cantor Colburn partner and trial attorney Andrew Ryan and litigation associate Chad Dever, Ph.D., examines the new procedures.  Ryan chairs the firm's Post Grant Practice Group, one of the first of its kind in the country.

Law360 quoted several attorneys about the Nautilus Inc. v. Biosig Instruments Inc. decision and amongst them was Cantor Colburn’s Andrew C. Ryan.

Cantor Colburn was nationally ranked for patent litigation by Corporate Counsel magazine in its October 2013 issue. Cantor Colburn’s dedicated team of litigation attorneys have decades of experience in presenting technically complex matters for trial in front of judges and juries. A partner participates in every facet of the case, bringing results that count for the client. And at each phase of the litigation, Cantor Colburn seeks practical strategies to achieve a prompt, efficient resolution of the dispute.

Cantor Colburn Partner and Post Grant Chair Andrew C. Ryan will discuss Medical Device Patents Infringement and Enforcement: Monitoring, Diligence, Alternatives, Path of Enforcement, in a live 90-minute premium CLE video webinar with interactive Q&A on Tuesday, December 5, 2023.

Cantor Colburn partner Andrew C. Ryan will present, "PlasmaCAM, Inc. v. CNCElectronics, LLC - Infringement of licensing" during the annual Joint Patent Practice Continuing Legal Education (JPPCLE) Seminar on June 15, 2022 in Iselin, New Jersey. 

Andy Ryan will be a panelist at the Joint Patent Practice CLE on May 2, 2019 in New York City. His panel will be on patents found invalid under Section 112 for lack of written description and enablement, including the cases D Three Enterprises, LLC V. Sunmodo Corporation et al 2017-1909 et al (Fed. Cir.) May 21, 2018 and Trustees of Boston University v. Everlight Electronics Co., LTD, et al, 2016-2576 (Fed. Cir. July 25, 2018). \

Pharmaceutical Litigation Chair Steve Coyle will be a panelist at the Paragraph IV Disputes Conference in New York City, April 29-30, 2019.  Cantor Colburn has a dedicated Pharmaceutical Practice Group comprised of experienced litigators, Ph.D. chemists, and patent attorneys expert in other supporting technologies. Also attending from Cantor Colburn are Michael Cantor, Andrew Ryan and Nicholas Geiger. 

Cantor Colburn is sponsoring the Paragraph IV Disputes conference in New York City on April 23-25, 2018.  Cantor Colburn has a dedicated Pharmaceutical Practice Group comprised of experienced litigators, Ph.D. chemists, and patent attorneys.

Cantor Colburn partner Andrew C. Ryan will present, "Revisions to PTAB Rules" during the 32nd annual Joint Patent Practice Continuing Legal Education (JPPCLE) on April 21, 2016 in New York, New York. 

Andy is a trial lawyer with over a decade of experience representing plaintiffs and defendants in patent cases and other complex litigation matters. He also has significant experience in adversarial proceedings in the Patent and Trademark Office and chairs the firm’s Post Grant Review Practice Group. He regularly counsels clients on adversarial PTO proceedings co-pending with litigation.